智通财经网·2025-09-11 03:12Core Viewpoint - Rongchang Biopharma (09995) has seen a significant stock movement following the acceptance of its innovative drug, Tai Tasi Pi, for the treatment of Sjögren's syndrome by the National Medical Products Administration (NMPA) in China, marking a potential breakthrough in the field [1] Company Summary - Rongchang Biopharma's stock opened down over 7% but later rebounded to a 5.13% increase, trading at 106.6 HKD with a transaction volume of 805 million HKD [1] - The company announced that Tai Tasi Pi, a dual-target fusion protein drug, is the first of its kind globally to submit a marketing application for Sjögren's syndrome [1] - The drug has received Fast Track designation from the FDA in the United States and has been approved for Phase III clinical trials for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG) in China [1] - Rongchang Biopharma has entered into a licensing agreement with Vor Bio, granting Vor Bio exclusive rights to develop and commercialize Tai Tasi Pi outside of Greater China [1]